Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Stemline Therapeutics Stock Fell 36.9% This Morning

By Maxx Chatsko – Feb 2, 2017 at 12:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage oncology company is facing the same hurdles as better-known peers when it comes to next-generation immunotherapy development.

Man with his face down on his desk in front of a declining stock chart on the wall behind him.

Image source: Getty Images.

What happened

Shares of Stemline Therapeutics (STML) tumbled nearly 37% this morning after investors learned that a patient died in a clinical trial involving its lead drug candidate, SL-401. The news was not reported by the company, but confirmed by the patient's family and first reported by Adam Feuerstein of TheStreet. 

So what

Not hearing the news directly from management is bad enough, but the death occurred the day before a Jan. 19 stock offering for $45 million. Worse still, this is the third death to occur in a clinical trial involving SL-401 from a side effect known as capillary leak syndrome, a form of low blood pressure. The company had responded to previous patient deaths by altering dosing regimens, so the recent death hints that the drug may not be safe enough for human use in its current form or dosing.

Safety concerns now seem likely to derail an otherwise effective drug candidate -- an increasingly common theme for next-generation immunotherapy treatments. As Feuerstein writes, in earlier clinical trials "SL-401 has demonstrated robust overall tumor response rates of 84%, including 56% complete or near-complete response in patients enrolled in its clinical trial." The company had previously expected to use phase 2 results to obtain marketing approval for the drug candidate, but that now could be in doubt.

Investors hopeful that Stemline Therapeutics can weather patient deaths in the same way as Juno Therapeutics may want to consider the stark differences between the two. Juno Therapeutics had over $820 million in cash on hand at the end of September thanks to fully committed collaboration partners. In other words, it has a war chest that allows it to potentially make it through clinical holds and safety reviews or worse. By contrast, Stemline Therapeutics ended September with $50 million in cash on hand. The recent $45 million stock offering will help, but it may not be enough to overcome extra regulatory scrutiny or, worse, abandoning a once-promising drug altogether.

Now what

This is yet another reminder for investors that efficacy and safety go hand in hand to get a drug candidate onto the market. Despite promising early results for next-generation immunotherapy treatments, the inability to control fatal side effects -- likely stemming from our lack of understanding of biology -- could severely limit their advance. For now, investors will need to await an update from Stemline Therapeutics, but it certainly doesn't look very encouraging.

Maxx Chatsko has no position in any stocks mentioned. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.